Skip to content

Study · In vitro (cells) · 1999

1 result

Insulin-like growth factor binding protein-3 is secreted as a phosphoprotein by human breast cancer cells.

Pattison ST, Fanayan S, Martin JL

Molecular and cellular endocrinology1 Oct 1999Cited by 5 (Europe PMC)

PMID10612431 (opens in a new tab)DOI10.1016/s0303-7207(99)00132-x (opens in a new tab)PepBankPUB-10612431
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In Hs578T breast cancer cells, [LR3]IGF-I did not reduce the proportion of phosphorylated IGFBP-3, whereas IGF-I did.

    In plain wordsIn lab tests on breast cancer cells, an IGF-I analogue did not change IGFBP-3 phosphorylation, while natural IGF-I did.

    Peptide
    IGF-1 LR3
    Outcome
    No significant changeProportion of phosphorylated IGFBP-3 in conditioned medium
    Study

    humann: not reported in source

    Hs578T breast cancer cells
    Comparator
    Native IGF-I
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IGF-I, but not [LR3]IGF-I, reduced the proportion of phosphorylated IGFBP-3 in Hs578T conditioned medium, consistent with increased release of non-phosphorylated, cell-associated IGFBP-3.
    1 context sentence
    Summary · context
    In this study, we have examined phosphorylation of IGFBP-3 in two breast cancer cell lines: the estrogen receptor negative (ER-ve) Hs578T cell line in which IGFBP-3 is normally expressed, and ER+ve T47D breast cancer cells transfected with IGFBP-3 cDNA (T47D(BP-3)) and therefore expressing IGFBP-3 constitutively.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.